1. Home
  2. CELC vs ZH Comparison

CELC vs ZH Comparison

Compare CELC & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • ZH
  • Stock Information
  • Founded
  • CELC 2011
  • ZH 2011
  • Country
  • CELC United States
  • ZH China
  • Employees
  • CELC N/A
  • ZH N/A
  • Industry
  • CELC Medical Specialities
  • ZH Business Services
  • Sector
  • CELC Health Care
  • ZH Consumer Discretionary
  • Exchange
  • CELC Nasdaq
  • ZH Nasdaq
  • Market Cap
  • CELC 440.0M
  • ZH 421.4M
  • IPO Year
  • CELC 2017
  • ZH 2021
  • Fundamental
  • Price
  • CELC $57.43
  • ZH $5.19
  • Analyst Decision
  • CELC Strong Buy
  • ZH Strong Buy
  • Analyst Count
  • CELC 5
  • ZH 1
  • Target Price
  • CELC $53.60
  • ZH $4.70
  • AVG Volume (30 Days)
  • CELC 906.9K
  • ZH 451.7K
  • Earning Date
  • CELC 08-14-2025
  • ZH 08-27-2025
  • Dividend Yield
  • CELC N/A
  • ZH N/A
  • EPS Growth
  • CELC N/A
  • ZH N/A
  • EPS
  • CELC N/A
  • ZH 0.22
  • Revenue
  • CELC N/A
  • ZH $439,821,184.00
  • Revenue This Year
  • CELC N/A
  • ZH N/A
  • Revenue Next Year
  • CELC N/A
  • ZH $7.46
  • P/E Ratio
  • CELC N/A
  • ZH $23.06
  • Revenue Growth
  • CELC N/A
  • ZH N/A
  • 52 Week Low
  • CELC $7.58
  • ZH $3.13
  • 52 Week High
  • CELC $63.06
  • ZH $6.32
  • Technical
  • Relative Strength Index (RSI)
  • CELC 64.38
  • ZH 65.10
  • Support Level
  • CELC $50.44
  • ZH $4.64
  • Resistance Level
  • CELC $63.06
  • ZH $5.27
  • Average True Range (ATR)
  • CELC 3.17
  • ZH 0.23
  • MACD
  • CELC -0.47
  • ZH 0.03
  • Stochastic Oscillator
  • CELC 60.71
  • ZH 88.41

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About ZH Zhihu Inc. (every two of each representing one ordinary share)

Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.

Share on Social Networks: